NCT06888830 2025-06-19A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid TumourShanghai Junshi Bioscience Co., Ltd.Phase 1/2 Recruiting374 enrolled